Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in first-line advanced urothelial carcinoma
NCT03898180Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2019
- Primary completion
- Jul 2021
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of lenvatinib in urothelial carcinoma (UC), sponsored by Merck & Co. Primary endpoints: Progression-free Survival at 25 months and Overall Survival at 25 months. Started May 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03898180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898180.